舌下减敏疗法治疗花粉过敏成效极高

纽约（路透社健康报章时尚杂志）12月21日电—据《变态反应，痛风及免疫学年鉴》时尚杂志11月刊一篇报道，舌下减敏医学上（SLIT）放射治疗花粉所致的发炎过敏成效高。“能用SLIT减少鼻炎的并发症及药物消费，减缓社会上经济负担，”意大利Genoa学院Giovanni PassalacquaDr说。“先前早已有加大注射医学上减缓社会上负担，但这是首次对实用医学上（SLIT）透过严格分析的结果。”PassalacquaDr及其同僚们对花粉所致的关节炎鼻炎和痛风治果透过研究，分析能用SLIT为基础常规放射治疗及单独能用常规放射治疗的开支及。研究人员报道，SLIT使63.1%的患者呕吐改善，并防止51.8%的患者消失痛风，而单独分析方法常规医学上仅仅使23.2%的患者呕吐改善，防止28.9%的患者消失痛风。而且同常规放射治疗相比，SLIT的单独及间接花费均增高：SLIT患者放射治疗的总体花费低于国家医疗卫生系统预测的4年内单独药物放射治疗花费，并且低于社会上公众预测的2年内单独药物放射治疗花费。“SLIT并无法算是加大注射医学上的竞争对手，” PassalacquaDr解释说，“而是将其作为放射治疗方法的另一选择。它最大的优点在于其最优的可靠性和患者的易给予性。”“SLIT在美国未曾正式分析方法，尽管一些变态反应专家分析方法它（并且争得了令人满意的结果），” PassalacquaDr说。“欧洲情况完全相异，SLIT在很多国家里面广泛分析方法（如意大利，荷兰，法国，西班牙，葡萄牙，希腊及匈牙利）。”当前的问题是SLIT未曾得不到FDA的批准，“PassalacquaDr可用道。“受到FDA大力支持的医学研究准备透过里面，并有望得不到批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma Max Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

校对：蓝色幻想